Why the study?
Does FFR-guided PCI reduce 1-year MACE in patients with CCS and NSTE-ACS compared to angiography-guided PCI?
Does FFR-guided PCI reduce 1-year MACE in patients with CCS and NSTE-ACS compared to angiography-guided PCI?
Answers are grounded in this paper and cite their sources.
FFR-guided PCI reduces 1-year MACE compared to angiography-guided PCI in patients with CCS and NSTE-ACS, primarily by reducing peri-procedural MI.
For the podcast associated with this article, please visit https://academic.oup.com/eurheartj/pages/Podcasts. This Issue contains a Special Article entitled ‘Delivering a European Union cardiovascular health plan: from building momentum to political action’ by Donna Fitzsimons from the Queen's University Belfast, UK, and colleagues which discusses the transversal relevance of cardiovascular disease (CVD) and the need for strategic commitment to cardiovascular (CV) health at a political level.1 Such stark realities beg the question, why is CVD so neglected? One of the key problems has been the lack of an effective international policy to drive research and innovation implementation. It is estimated that the EU Beating Cancer Plan provided 4 billion Euros of much needed investment in cancer treatment and care. It is therefore completely justifiable to establish a similar focus for CVD. To this end, the European Society of Cardiology has joined forces and built partnerships across sectors that advocate for driving strategic change. The launch of the European Alliance for Cardiovascular Health (EACH) was pivotal, bringing together 21 key proponents including patient groups, health technology organizations, and foundations. For the first time, all major heart health organizations signed up to the same call for a fully funded EU CV Health Plan. The next significant challenge lies in forging consensus on the specifics of this plan and its execution. This endeavour aims to ensure that all European Union (EU) citizens receive the high-quality CV prevention, care, and treatment they rightfully deserve. To achieve this, it is imperative to unite with key decision-makers across all EU member states, equipping them with precise health data tailored to the unique CV challenges within their jurisdictions. This approach will reinforce the unified call for an EU-wide CV health plan that incorporates tailored implementation strategies for each country. The Issue continues with a focus on ischaemic heart disease and epidemiology, prevention, and healthcare policies. The foundation of preventive cardiology relies on the assessment of CV risk using scores based on exposure to traditional risk factors and on genetic risk.2–8 However, risk models based on these risk factors provide only moderate discrimination and some are poorly calibrated, highlighting a need for improved approaches to risk assessment. In a State of the Art Review article entitled ‘Cardiovascular biomarkers for risk stratification in primary prevention’ Johannes T. Neumann from the University Medical Center Hamburg-Eppendorf in Germany, and colleagues provide an overview of the characteristics of a circulating biomarker that would promote its clinical use on the existing evidence behind CV biomarkers for risk stratification.9 Cardiovascular biomarkers, including cardiac troponins, natriuretic peptides, and inflammatory markers, can be used to reclassify CV risk, especially in individuals at intermediate risk, providing opportunities for optimization of primary prevention strategies. Hundreds of studies have described robust associations between CV biomarkers and incident CV events. However, the incremental value, when biomarkers were added to conventional risk factor models, has generally been modest in terms of improvement in model performance. The review also describes emerging proteomic techniques that enable high-throughput analysis of circulating proteins, presenting opportunities for improved CV risk prediction. Despite encouraging findings, challenges remain in integrating these biomarkers into clinical practice, and there is a need for evidence from clinical trials to demonstrate their cost-effective impact on reducing CV events. While biomarkers hold promise for enhancing CV prevention strategies, their routine application in clinical settings requires further innovation and investigation to establish clear treatment guidelines and optimize patient outcomes. Coronary blood flow is conventionally analysed as a continuous flow of blood through a tube with the input of energy in the epicardial coronary arteries and the principal resistance to flow in the arterioles and the small arteries. This model has been studied in detail and is accepted by all expert groups. In a State of the Art Review article entitled ‘Myocardial compression and recoil as determinants of coronary blood flow’ by Allan D. Sniderman from McGill University Health Centre—Royal Victoria Hospital in Montreal, Canada, and colleagues discuss how the coronary blood flow model is valid but incomplete.10 Coronary blood flow is not continuous. Coronary blood flow is phasic and asynchronous. During systole, at rest, there is no forward flow to the left ventricle in the epicardial coronary arteries; but there is forward flow in systole in the coronary veins. The blood forced during systole into the coronary veins is expelled from the coronary microcirculation by myocardial contraction and represents the compressible volume of the coronary microcirculation. During diastole, inflow of blood from the epicardial coronary artery begins abruptly, accelerated by myocardial recoil, refilling the compressible volume of the coronary microcirculation, and then flowing through the coronary vein. Accordingly, the hydrostatic energy in the epicardial coronary artery is not the only energy propelling blood through the coronary circulation. Myocardial compression and recoil also contribute. Disorders of myocardial compression and myocardial recoil in diastole should be considered in the differential diagnosis of disorders of the microcirculation. Thus, reduced coronary flow reserve in heart failure with preserved ejection fraction might be a consequence, rather than a cause, of myocardial dysfunction. Main results of the PRIME Collaboration study. CCS, chronic coronary syndrome; FFR, fractional flow reserve; IPD, individual patient data; MACE, major adverse cardiac events; NSTE-ACS, non-ST-elevation acute coronary syndrome; PCI, percutaneous coronary intervention.14 Fractional flow reserve (FFR) has been widely used as an invasive functional index to assess the haemodynamic severity of epicardial coronary stenoses to indicate or defer coronary revascularization (Class IA).11–13 Yet, randomized controlled trials (RCTs) comparing FFR-guided percutaneous coronary intervention (PCI) with angiography-guided PCI yielded mixed results. In a Meta-analysis article entitled ‘Fractional flow reserve vs angiography to guide percutaneous coronary intervention: an individual patient data meta-analysis’ by Fabio Mangiacapra from Campus Bio Medico University of Rome in Italy, and colleagues conduct an individual patient data (IPD) meta-analysis to consolidate current clinical indications and practice by selectively focusing on chronic coronary syndrome (CCS) patients with intermediate coronary lesions or non-culprit stenotic vessels in NSTE-ACS patients from RCTs comparing FFR-guided vs angiography-guided PCI.14 This meta-analysis focused on trials where FFR was used to assess intermediate coronary lesions in CCS or non-culprit vessels in non-ST-elevation acute coronary syndromes (NSTE-ACS). RCTs comparing FFR- vs angiography-guided PCI with a minimum follow-up of 1 year were searched. Studies lacking angiographic inclusion criteria or using FFR for culprit arteries in NSTE-ACS were excluded. Studies including patients with ST-elevation myocardial infarction (MI) or undergoing surgical revascularization could be included after censoring these two subgroups. The primary outcome was 1-year rate of major adverse cardiac events (MACE), defined as a composite of all-cause death, MI, and repeat revascularization. The secondary outcomes were a composite of all-cause death and MI, the individual components of the primary outcome, cardiac death, spontaneous MI, and procedural MI. Five RCTs were selected, including 2493 patients. More vessels underwent PCI in the angiography group (45% vs 30%, P < .001), with more stents implanted per patient (2.0 vs 1.5, P < .001). One-year MACE occurred in 14.7% of patients in the angiography group and 12.1% in the FFR group [hazard ratio (HR) .80; P = .046]. The risk of MI was significantly reduced in the FFR-guided group (HR .71, P = .031) (Figure 1). These outcomes were driven by a reduction in peri-procedural MI with FFR guidance, with no significant difference between groups in non-procedural MI, MACE between 30 days and 1 year, and secondary outcomes. The authors conclude that FFR-guided PCI is associated with reduced major adverse events in patients with CCS and NSTE-ACS due mainly to fewer peri-procedural MIs, with no differences in mortality or MACE beyond 30 days. The manuscript is accompanied by an Editorial by Adrian P. Banning from Oxford University Hospitals in the UK.15 The author concludes that for some individuals and industry, the limited penetration of the use of physiology in daily interventional practice has been a puzzle and frustration. Technical limitations regarding the handling properties of the wires, concerns about the side effects of infusions to induce hyperaemia, and limited catheter lab time are all cited as possible explanations. Reviewing and perhaps reappraising data collected over a period may have the benefit of reminding us about the validity of previous observations and perhaps serves to re-emphasize the message. Only time will tell whether these new collated data will increase the penetration of physiology into interventional decision-making. Graphical abstract20 Low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein B-containing lipoproteins, including lipoprotein(a) [Lp(a)], are directly associated with atherosclerosis.16–19 In a Fast Track Clinical Research article entitled ‘Low-density lipoprotein cholesterol, lipoprotein(a), and high-sensitivity C-reactive protein are independent predictors of cardiovascular events’ by Marcello Ricardo Paulista Markus from University Medicine Greifswald, Germany, and colleagues analyse associations of hyperlipidaemia and inflammation with the risk of incident MACEs in individuals with and without cholesterol-lowering medication therapy.20 Data from about 323 000 participants (56% women) aged 38 to 73 years from the UK Biobank were included. Longitudinal associations of LDL-C, Lp(a), and high-sensitivity C-reactive protein (hs-CRP), both individually and in combination, were analysed with the risk of incident MACEs using Cox regression models, stratified by cholesterol-lowering medication use. During a median follow-up of 13.7 years, 9.7% of participants had incident MACEs. One higher standard deviation in LDL-C, Lp(a), and hs-CRP was associated with a 13%, 8%, and 6% greater risk for MACEs in non-users and 11%, 7%, and 6% in cholesterol-lowering medication users, respectively. When combined, LDL-C, Lp(a), and hs-CRP demonstrated a synergistic effect. Compared with individuals with all three biomarkers at or below the 75th percentile, those with all three biomarkers above the 75th percentile had a 77% higher risk of incident MACEs among non-users and a 58% higher risk among those on cholesterol-lowering medications (Figure 2). The authors conclude that hyperlipidaemia and inflammation independently and synergistically contribute to an increased risk of incident cardiovascular events. The magnitude of risk is more closely related to serum biomarker concentrations than to the use or not of cholesterol-lowering medications. The prognostic role of Lp(a) and hs-CRP is also addressed in a second Fast Track Clinical Research contribution entitled ‘Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study’, Jordan Kraaijenhof from the University of Amsterdam in the Netherlands and colleagues address the validity and generalizability of this novel primary prevention strategy in a large prospective European cohort of initially healthy men and women.21 Plasma levels of LDL cholesterol, hs-CRP, and Lp(a) were measured at study entry in more than 17 000 participants from the EPIC-Norfolk study who were subsequently followed over a period of 20 years for MACEs. Competing risk- and multivariable-adjusted HRs and 95% confidence intervals for incident MACE across quintiles of each biomarker and sought evidence of independent as well as additive effects over time were calculated. During the 20-year follow-up, a total of 3249 MACEs occurred. Increasing quintiles of baseline LDL cholesterol, hs-CRP, and Lp(a) all predicted 20-year risks; the multivariable-adjusted HRs in a comparison of the top to bottom quintile were 1.78 for LDL cholesterol, 1.55 for hs-CRP, and 1.19 for Lp(a). Compared with individuals with no biomarker elevations, the multivariable-adjusted HRs for incident MACE were 1.33, 1.68, and 2.41 for those with one, two, or three biomarkers in the top quintile, respectively (all P < .001). Each biomarker demonstrated independent contributions to overall risk and findings were consistent in analyses stratified by sex. The authors conclude that a single combined measure of LDL cholesterol, hs-CRP, and Lp(a) among initially healthy European men and women is predictive of incident MACE during a 20-year period. These data replicate findings from a recent American cohort and strongly support universal screening for all three biomarkers in primary prevention. This contribution by Kraaijenhof et al. and the contribution by Markus et al. are accompanied by a common Editorial by Viviane Rocha from the University of Sao Paulo Medical School Hospital in Brazil.22 Rocha underscores that although a healthy lifestyle is essential for long-term cardiovascular health and should remain the cornerstone of all prevention strategies, personalized treatment approaches that may extend beyond statin therapy require a more tailored framework. The biomarkers LDL-C, hs-CRP, and Lp(a), a triad of modifiable targets reflecting distinct and biologically relevant pathways in atherosclerosis, offer a practical and scalable means for early and individualized prevention. Integrating these biomarkers with other modalities may further enhance risk detection and support even more personalized prevention strategies over the course of life. Time has probably come to include Lp(a) and hs-CRP in risk scores and in guidelines to guide preventive treatments. Primary percutaneous coronary intervention (PPCI) is the standard reperfusion strategy for patients with ST-elevation myocardial infarction (STEMI), especially when it can be performed within 120 min of initial diagnosis. Although regional networks have been well-established worldwide, inherent delays still exist from first medical contact (FMC) transfer to the catheterization laboratory (Cath Lab), during which no specific reperfusion therapy can be administered. In a Fast Track Clinical Research article entitled ‘Heparin administration at first medical contact vs immediately before primary percutaneous coronary intervention: the HELP-PCI trial’ by Jing Chen from the Renmin Hospital of Wuhan University, China, and colleagues aim to investigate the effects of pre-treatment with UFH at a full dose of 100 U/kg on the restoration of Thrombolysis in Myocardial Infarction flow grade (TFG-3) before PPCI in the infarct-related artery (IRA) of patients with STEMI.23 HELP-PCI was an investigator-initiated, randomized controlled trial conducted at 36 clinical centres in China. Patients with STEMI presenting ≤ 12 h after symptom onset undergoing PPCI were randomly assigned (1:1) to intravenous administration with UFH (100 U/kg) at FMC or in the Cath Lab through a catheter sheath. The primary endpoint was TFG-3 of IRA at diagnostic angiography before PPCI. The secondary outcome was complete epicardial and myocardial reperfusion after PPCI and major adverse cardiac and cerebrovascular events (MACCE; defined as the composite of all-cause death, cardiac death, heart failure hospitalizations, re-infarction, stent thrombosis, unplanned revascularization, and stroke) at 12 months. Safety outcome was 30-day Bleeding Academic Research Consortium (BARC) type ≥ 2 bleeding. A total of 999 patients with STEMI undergoing PPCI were randomly assigned to receive either UFH administration at FMC (n = 505) or in the Cath Lab (n = 494). The pre-treated population at FMC showed a higher frequency of TFG-3 of IRA compared with the Cath Lab group (24% vs 18%; P = .02). There were no significant differences in secondary endpoints or in the safety endpoint, including 12-month. The authors conclude that pre-treatment with loading-dose UFH at FMC is associated with an improvement of spontaneous reperfusion of IRA without increasing the risk of major bleeding. The manuscript is accompanied by an Editorial by David Erlinge and Sasha Koul from Lund University in Sweden.24 The authors expect that, together with previous studies, the HELP-PCI trial will change guidelines and ‘open up the doors’ for a stronger recommendation for using heparin in the pre-hospital setting for STEMI treated with primary PCI. Historically, it is interesting to remember that one of the strongest pieces of evidence for primary PCI compared with thrombolysis comes from the DANAMI-2 trial in which the primary PCI group was treated with 10 000 U of heparin at the FMC. An interesting future combination could be to add a short-acting intravenous P2Y12 inhibitor to aspirin and heparin at first medical contact, since it has the same rapid onset and even faster offset than heparin, but this needs to be tested in randomized trials. Increasing evidence suggests that COVID-19 survivors experience long-term cardiovascular complications possibly through development of vascular damage. In a Clinical Research article entitled ‘Accelerated vascular ageing after COVID-19 infection: the CARTESIAN study’, Rosa Maria Bruno from Paris Cité University in France, and colleagues aim to investigate whether accelerated vascular ageing occurs after COVID-19 infection, and if so, identify its determinants.25 This prospective, multicentric, cohort study, included 34 centres in 16 countries worldwide, in 4 groups of participants: (i) COVID-19-negative controls; individuals not with recent exposure to patients in with recent exposure to and patients in with recent exposure to The outcome was an biomarker of large artery individuals years, women) were for all groups showed higher and for groups P < P = and P = vs In differences were significant in women < for but not in were associated with higher of disease severity and cardiovascular < .001). The authors conclude that COVID-19 is associated with early vascular ageing in the especially in The manuscript is accompanied by an Editorial by D. and from University in and Medical School in The authors that the CARTESIAN study an to and health vascular is and with a of For routine cardiovascular risk stratification in patients with COVID-19 be Although CARTESIAN was not a study with these findings that further should be traditional risk factor as well as patient about the disease For the findings studies into differences in and The CARTESIAN study the that COVID-19 has aged especially for The is whether can modifiable targets to this in future of and adverse outcomes in those with vascular The implementation of European Society of Cardiology guidelines for the use of cardiac in CCS was to be in the In a article entitled and outcomes of chronic coronary the from in Italy, and colleagues aim to assess how characteristics and coronary disease based on were associated with treatment The authors focus on the impact of diagnostic pathways on early treatment and that in more than patients with CCS treatment is still to specific disease and guidelines a of medical therapy was to coronary revascularization of The authors conclude that the results how the of medical treatment revascularization is still not by the individual disease which can be defined by as by both and new CCS with possible impact on the outcomes. The Issue is also by a In a entitled on in patients with and from Hospital of Medical University in China, and Hospital in China, on the entitled in patients with a randomized trial’ by et from the University of in the The that this of the European will the of its from the to and for with of this
No takes yet. Share an insight, caveat, or question.
Filippo Crea (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: